Evidence map›Paper›PMID 42163437›Full record

ArticleHIV research & clinical practice2026

Perceptions of young people living with HIV and caregivers in Botswana on analytical treatment interruption studies: a qualitative approach.

Catherine K Koofhethile, Poloko Kebaabetswe, Ontlametse T Choga, Fikile Ditshweu, Pearl Ntshonga, Bonolo R Molefe, Oganne Batlang, Patrick Mokgethi, Tsholofelo Mosielele, Phenyo Sabone and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV research & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Catherine K KoofhethileBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0001-5475-413X
Poloko KebaabetsweBotswana Harvard Health Partnership, Gaborone, Botswana.
Ontlametse T ChogaBotswana Harvard Health Partnership, Gaborone, Botswana.
Fikile DitshweuBotswana Harvard Health Partnership, Gaborone, Botswana.
Pearl NtshongaBotswana Harvard Health Partnership, Gaborone, Botswana.
Bonolo R MolefeBotswana Harvard Health Partnership, Gaborone, Botswana.
Oganne BatlangBotswana Harvard Health Partnership, Gaborone, Botswana.
Patrick MokgethiBotswana Harvard Health Partnership, Gaborone, Botswana.
Tsholofelo MosieleleBotswana Harvard Health Partnership, Gaborone, Botswana.
Phenyo SaboneBotswana Harvard Health Partnership, Gaborone, Botswana.
Pearl KgoreletsoBotswana Harvard Health Partnership, Gaborone, Botswana.
Amantle GouweBotswana Harvard Health Partnership, Gaborone, Botswana.
Keitumetse MosepeleBotswana Harvard Health Partnership, Gaborone, Botswana.
Rashida MajolaBotswana Harvard Health Partnership, Gaborone, Botswana.
Dorcas MaruapulaBotswana Harvard Health Partnership, Gaborone, Botswana.
Kaelo SeatlaBotswana Harvard Health Partnership, Gaborone, Botswana.
Wonderful ChogaBotswana Harvard Health Partnership, Gaborone, Botswana.
Gbolahan AjibolaBotswana Harvard Health Partnership, Gaborone, Botswana.
Joseph MakhemaBotswana Harvard Health Partnership, Gaborone, Botswana.
Gaerolwe MashetoBotswana Harvard Health Partnership, Gaborone, Botswana.
Xu YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Sikhulile MoyoBotswana Harvard Health Partnership, Gaborone, Botswana.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Shahin LockmanBotswana Harvard Health Partnership, Gaborone, Botswana.
Roger ShapiroBotswana Harvard Health Partnership, Gaborone, Botswana.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Expansion of research and mentoring to improve birth outcomes and treatment outcomes among HIV-affected children in BotswanaK24AI131924 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Roger L Shapiro · 2018 to 2026
$1.6M
Finding a pathway to HIV cure among adolescents on long-standing ART in Botswana through reservoir analysis, analytic treatment interruption, and biomarker assessmentK43TW012848 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI Catherine Kegakilwe Koofhethile · 2024 to 2026
$340k
Developing Botswana Laboratory Capacity in HIV Genomics and HIV CureG11TW012503 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI GASEITSIWE, SIMANI · 2023 to 2025
$297k
FIC NIH HHS D43 TW009610FIC NIH HHS G11 TW012503FIC NIH HHS K43 TW012848Gates Foundation INV-033558NIAID NIH HHS K24 AI131924NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

backgroundCurrent research suggests that post-treatment HIV control may be possible for some people following antiretroviral treatment (ART) interruption. Although closely monitored analytic treatment interruption (ATI) studies can be performed safely and are crucial to determine who may no longer require ART, currently it is unknown how acceptable these studies will be in Botswana.

aimTo determine the knowledge, attitudes and acceptability of ATI-inclusive studies in Botswana.

methodsWe employed a non-randomized purposive design to recruit study participants. We conducted face-to-face open-ended interviews with 12 young people living with HIV and 8 caregivers, 8 healthcare providers and 4 community advocates in Gaborone and Palapye.

resultsThirty-two (32) participants consented to be interviewed. The median age of young people living with HIV was 29 years. All young people living with HIV indicated that they were on ART and acknowledged the benefits of being on ART. All young people living with HIV were unaware of ATIs, whereas 6 out of 8 caregivers, 6 out of 8 healthcare providers and 2 out of 4 community advocates had never heard of ATIs. Most participants found ATI research to be acceptable and believed that it would be beneficial provided there were adequate risk mitigations in place.

conclusionsATI studies were acceptable to both young people living with HIV and their caregivers. There was limited knowledge about ATI, highlighting a need to inform communities and health care providers on the scientific aspects of ATI and HIV cure research.

Indexed as

Anti-HIV AgentsCaregiversHealth Knowledge, Attitudes, PracticeHIV InfectionsAdolescentAdultBotswanaFemaleHumansInterviews as TopicMaleQualitative ResearchTreatment InterruptionYoung AdultAnti-HIV AgentsATIHIV cure researchperceptionsqualitativeyoung-people living with HIV

Identifiers

PMID42163437
PMCPMC13439527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.